Understanding Exposure-Receptor Occupancy Relationships for Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators across a Range of Preclinical and Clinical Studies

被引:3
作者
Bennett, Kirstie A. [1 ]
Sergeev, Eugenia [1 ]
MacSweeney, Cliona P. [1 ]
Bakker, Geor [1 ]
Cooper, Anne E. [1 ]
机构
[1] Sosei Heptares, Steinmetz Bldg,Granta Pk, Cambridge CB21 6DG, Cambs, England
关键词
LEVODOPA-INDUCED DYSKINESIA; IN-VITRO; BINDING; PET; IDENTIFICATION; ANTAGONISTS; SUBTYPE-5; LIGAND; BRAIN; BASIMGLURANT;
D O I
10.1124/jpet.120.000371
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The metabotropic glutamate receptor 5 (mGlu(5)) is a recognized central nervous system therapeutic target for which several negative allosteric modulator (NAM) drug candidates have or are continuing to be investigated for various disease indications in clinical development. Direct measurement of target receptor occupancy (RO) is extremely useful to help design and interpret efficacy and safety in nonclinical and clinical studies. In the mGlu(5) field, this has been successfully achieved by monitoring displacement of radiolabeled ligands, specifically binding to the mGlu(5) receptor, in the presence of an mGlu(5) NAM using in vivo and ex vivo binding in rodents and positron emission tomography imaging in cynomolgus monkeys and humans. The aim of this study was to measure the RO of the mGlu(5) NAM HTL0014242 in rodents and cynomolgus monkeys and to compare its plasma and brain exposure-RO relationships with those of clinically tested mGlu(5) NAMs dipraglurant, mavoglurant, and basimglurant. Potential sources of variability that may contribute to these relationships were explored. Distinct plasma exposure-response relationships were found for each mGlu(5) NAM, with >100-fold difference in plasma exposure for a given level of RO. However, a unified exposure-response relationship was observed when both unbound brain concentration and mGlu(5) affinity were considered. This relationship showed <10-fold overall difference, was fitted with a Hill slope that was not significantly different from 1, and appeared consistent with a simple E-max model. This is the first time this type of comparison has been conducted, demonstrating a unified brain exposure-RO relationship across several species and mGlu(5) NAMs with diverse properties. SIGNIFICANCE STATEMENT Despite the long history of mGlu(5) as a therapeutic target and progression of multiple compounds to the clinic, no formal comparison of exposure-receptor occupancy relationships has been conducted. The data from this study indicate for the first time that a consistent, unified relationship can be observed between exposure and mGlu(5) receptor occupancy when unbound brain concentration and receptor affinity are taken into account across a range of species for a diverse set of mGlu(5) negative allosteric modulators, including a new drug candidate, HTL0014242.
引用
收藏
页码:157 / 168
页数:12
相关论文
共 47 条
  • [1] Receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant P2X7 antagonists in the rat
    Able, S. L.
    Fish, R. L.
    Bye, H.
    Booth, L.
    Logan, Y. R.
    Nathaniel, C.
    Hayter, P.
    Katugampola, S. D.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2011, 162 (02) : 405 - 414
  • [2] Ametamey SM, 2007, J NUCL MED, V48, P247
  • [3] [3H]methoxymethyl-3-[(2-methylyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain:: In vitro and in vivo characterization
    Anderson, JJ
    Rao, SP
    Rowe, B
    Giracello, DR
    Holtz, G
    Chapman, DF
    Tehrani, L
    Bradbury, MJ
    Cosford, NDP
    Varney, MA
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) : 1044 - 1051
  • [4] Archer T, 2016, CURR TOP BEHAV NEURO, V29, P295, DOI 10.1007/7854_2015_415
  • [5] A multi-atlas based method for automated anatomical Macaca fascicularis brain MRI segmentation and PET kinetic extraction
    Ballanger, Benedicte
    Tremblay, Leon
    Sgambato-Faure, Veronique
    Beaudoin-Gobert, Maude
    Lavenne, Franck
    Le Bars, Didier
    Costes, Nicolas
    [J]. NEUROIMAGE, 2013, 77 : 26 - 43
  • [6] Bennett K, 2014, P BRIT PHARM SOC LEI
  • [7] Expression of metabotropic glutamate receptor subtype mRNA (mGluR1-8) in human cerebellum
    Berthele, A
    Platzer, S
    Laurie, DJ
    Weis, S
    Sommer, B
    Zieglgänsberger, W
    Conrad, B
    Tölle, TR
    [J]. NEUROREPORT, 1999, 10 (18) : 3861 - 3867
  • [8] The mGluR5 Negative Allosteric Modulator Dipraglurant Reduces Dyskinesia in the MPTP Macaque Model
    Bezard, Erwan
    Pioli, Elsa Y.
    Li, Qin
    Girard, Francoise
    Mutel, Vincent
    Keywood, Charlotte
    Tison, Francois
    Rascol, Olivier
    Poli, Sonia M.
    [J]. MOVEMENT DISORDERS, 2014, 29 (08) : 1074 - 1079
  • [9] Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile)
    Christopher, John A.
    Aves, Sarah J.
    Bennett, Kirstie A.
    Dore, Andrew S.
    Errey, James C.
    Jazayeri, Ali
    Marshall, Fiona H.
    Okrasa, Krzysztof
    Serrano-Vega, Maria J.
    Tehan, Benjamin G.
    Wiggin, Giselle R.
    Congreve, Miles
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (16) : 6653 - 6664
  • [10] Population Pharmacokinetic and Exposure-dizziness Modeling for a Metabotropic Glutamate Receptor Subtype 5 Negative Allosteric Modulator in Major Depressive Disorder Patients
    Cosson, Valerie
    Schaedeli-Stark, Franziska
    Arab-Alameddine, Mona
    Chavanne, Clarisse
    Guerini, Elena
    Derks, Michael
    Mallalieu, Navita L.
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2018, 11 (05): : 523 - 531